Education
About Us
Working with TipRanks
Follow Us
Osteopore Ltd. (AU:OSX)
ASX:OSX
OSX Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.05
Previous CloseN/A
Volume70.28K
Average Volume (3M)2.16M
Market Cap
AU$4.10M
Enterprise ValueAU$1.83M
Total Cash (Recent Filing)AU$626.97K
Total Debt (Recent Filing)AU$198.80K
Price to Earnings (P/E)―
Beta4.64
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding512,501,830
10 Day Avg. Volume675,672
30 Day Avg. Volume2,156,422
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.65
Price to Sales (P/S)0.37
P/FCF Ratio-0.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent multi-year revenue growth (~1.5M to ~3.1M from 2020–2025) signals expanding clinical adoption and market traction for Osteopore’s bioresorbable implants. This trend supports durable top-line momentum and provides a base for scaling operations and improving unit economics.
High Gross MarginA ~53% gross margin in 2025 indicates product-level pricing power and differentiated technology. Durable gross margins support reinvestment in R&D and commercialization, improving prospects for future profitability as fixed costs are leveraged with higher volume.
Reduced LeverageMaterial debt reduction lowers interest and refinancing risk, improving financial flexibility. For a capital-light medtech business, reduced leverage enhances runway for commercialization initiatives and reduces the near-term funding burden versus prior years.
Bears Say
Persistent Net LossesLarge recurring net losses and negative operating/free cash flow demonstrate ongoing cash burn and reliance on external financing. This structural shortfall constrains the company’s ability to self-fund expansion, increases dilution/refinancing risk, and can limit long-term strategic flexibility.
Negative Shareholders' EquityNegative equity is a structural weakness that reduces balance-sheet resilience and may impair access to traditional financing. It raises solvency concerns for stakeholders and can hamper the company’s ability to invest in manufacturing scale-up or pursue strategic partnerships without recapitalization.
Limited Cash Generation & Smaller Capital BaseA shrinking asset base and weak cash generation indicate constrained capacity to scale manufacturing, expand clinical trials, or absorb regulatory/commercial costs. This structural limitation increases dependence on external funding and may slow long-term execution of growth plans.
Osteopore Ltd. News
OSX FAQ
What was Osteopore Ltd.’s price range in the past 12 months?
Osteopore Ltd. lowest share price was <AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Osteopore Ltd.’s market cap?
Osteopore Ltd.’s market cap is AU$4.10M.
When is Osteopore Ltd.’s upcoming earnings report date?
Osteopore Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 173 days.
How were Osteopore Ltd.’s earnings last quarter?
Osteopore Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Osteopore Ltd. overvalued?
According to Wall Street analysts Osteopore Ltd.’s price is currently Overvalued.
Does Osteopore Ltd. pay dividends?
Osteopore Ltd. does not currently pay dividends.
What is Osteopore Ltd.’s EPS estimate?
Osteopore Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Osteopore Ltd. have?
Osteopore Ltd. has 512,501,830 shares outstanding.
What happened to Osteopore Ltd.’s price movement after its last earnings report?
Osteopore Ltd. reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of Osteopore Ltd.?
Currently, no hedge funds are holding shares in AU:OSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Osteopore Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
AU:OSX Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Bearish
Bullish news 40%
Bearish news 60%
Bearish news 60%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.79%
12-Months-Change
Fundamentals
Return on Equity
-487.52%
Trailing 12-Months
Asset Growth
-7.78%
Trailing 12-Months
Company Description
Osteopore Ltd.
Osteopore Limited designs, develops, and markets bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery applications in Singapore, Australia, and internationally. Its technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. The company offers Osteoplug, a bioresorbable implant, which is used for covering trephination burr holes in neurosurgery; and Osteomesh, a bioresorbable implant that is used in craniofacial surgery to repair various types of fractures, such as orbital floor fracture, as well as to fill surgical defects. Osteopore Limited has a collaboration agreement with Livingstone Health Holding Limited to jointly develop new applications and products for regenerating bone and tissue. The company was incorporated in 2003 and is headquartered in Singapore.
Technical Analysis
Orthocell Ltd
―
Aroa Biosurgery Ltd
―
ImExHS Limited
―
Emyria Ltd
―
Arovella Therapeutics Limited
―